Six months of maintenance chemotherapy improved OS in children with high-risk rhabdomyosarcoma.
Investigators have discovered that clofarabine and cladribine may be used as a targeted therapy in diseases where CD99 plays a critical role, including Ewing sarcoma and auto-immune disorders.
A comparison of margin classification systems revealed some differences in their ability to determine local recurrence risk for soft-tissue sarcoma.
A phase II study found that the immunotherapy agent pembrolizumab has meaningful clinical activity in patients with two subtypes of advanced sarcoma.
In this interview we discuss the phase III trial of aldoxorubicin in patients with advanced soft-tissue sarcoma, which showed improved efficacy and reduced toxicity over doxorubicin.
Treatment with the PD-1 inhibitor pembrolizumab plus metronomic cyclophosphamide had limited activity in patients with soft-tissue sarcomas and gastrointestinal stromal tumors.
In this review we discuss preoperative diagnosis and the role of pathology, and we summarize the current literature regarding the management of uterine sarcomas.
Survivors of childhood Ewing sarcoma have substantial risk for late mortality and subsequent neoplasms, according to a long-term follow-up study.
A genomic analysis of Ewing sarcoma found substantial epigenetic heterogeneity both between tumors and within tumors, highlighting the need to consider non-genetic aspects in cancer biology and treatment.
A study examining predictors of outcome following relapse of primary retroperitoneal sarcoma found that time to local recurrence or distant metastasis significantly predict survival, and that patients who undergo resection for the recurrent disease have better survival than others.